NCT00570284已完成1 期
A Phase Ib Open-label, Multicenter Cross-over Study to Investigate the Effect of Food on the Rate and Extent of Oral LBH589 Absorption in Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Levels of LBH589 in the blood
研究概览
简要总结
The primary purpose of this study is to evaluate the effect of food on oral LBH589 in adult patients with advanced solid tumors. This study will also evaluate the safety and efficacy of LBH589 in adult patients with advanced solid tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
LBH589
Experimental
干预措施: LBH589 (Drug)
结局指标
主要结局
Levels of LBH589 in the blood
时间窗: every week for the first 3 weeks
次要结局
- Efficacy, Safety and tolerability(throughout study to 28 days after last treatment)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell LymphomaAdult patients with stages IB to IVA mycosis fungoides (MF) or Sézary syndrome (SS). Patients with any history of visceral involvement of their CTCL will not be eligible for this study. Patients with Sézary syndrome and bone marrow involvement are eligible. All patients must have received at least two prior systemic treatment regimens for their MF or SS.MedDRA version: 14.1Level: LLTClassification code 10011679Term: Cutaneous T-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-000880-27-ESovartis Farmacéutica, S.A.139
进行中（未招募）
不适用
A Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-Cell LymphomaEUCTR2006-000880-27-ITOVARTIS FARMA118
终止
2 期
Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic PhaseChronic Myeloid Leukemia in Chronic PhaseNCT00451035Novartis Pharmaceuticals29
进行中（未招募）
不适用
A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy - NDMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomamultiple myelomaEUCTR2006-004087-31-ITOVARTIS FARMA144
进行中（未招募）
不适用
A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell LymphomaEUCTR2006-000880-27-HUovartis Pharma Services AG118